

Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

NCT07209462

Status	RECRUITING
Phase	Phase 2
Sponsor	Mirum Pharmaceuticals, Inc.
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (7)

- Willing and able to provide signed informed consent/assent. Where local regulations permit inclusion of participants deemed unable to provide informed consent, a legally authorized representative must provide informed consent on the participant's behalf, and the participant must provide assent if applicable.
- Male, 13-45 years of age (inclusive)
- Weight e30 kg and BMI between 18 and 36 kg/m2 (inclusive) at the screening visit
- Diagnosis of FXS with a molecular genetic e200 CGG repetitions .
- Able to perform the PVT and ORRT of the NIH-TCB
- ... and 2 more (see full listing online)

Exclusion (1)

- History of or current medical condition other than FXS and related issues that would place the participant at higher risk from study participation

Locations (15 total)

Southwest Autism Research & Resource Center, Phoenix, Arizona, United States
Amnova Clinical Research, LLC, Irvine, California, United States
Children's Hospital of Orange County - Pediatric Subspecialty, Orange, California, United States
... and 12 more locations